Patents by Inventor John Babcook
John Babcook has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230390354Abstract: Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.Type: ApplicationFiled: February 21, 2023Publication date: December 7, 2023Applicant: ZYMEWORKS BC INC.Inventors: Geoffrey C. WINTERS, Alexander Laurence MANDEL, James R. RICH, Bradley John HEDBERG, Tom Han Hsiao HSIEH, Elyse Marie Josée BOURQUE, John BABCOOK
-
Publication number: 20230235062Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.Type: ApplicationFiled: November 1, 2022Publication date: July 27, 2023Inventors: CHRISTOPHE QUEVA, MICHELLE MORROW, SCOTT HAMMOND, MARAT ALIMZHANOV, JOHN BABCOOK, IAN FOLTZ, JASPAL SINGH KANG, LAURA SEKIROV, MELANIE BOYLE, MATTHIEU CHODORGE, ROSS A. STEWART, KATHLEEN ANN MULGREW
-
Patent number: 11617777Abstract: Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.Type: GrantFiled: February 11, 2019Date of Patent: April 4, 2023Inventors: Geoffrey C. Winters, Alexander Laurence Mandel, James R. Rich, Bradley John Hedberg, Tom Han Hsiao Hsieh, Elyse Marie Josée Bourque, John Babcook
-
Patent number: 11208497Abstract: The present disclosure provides light chain polypeptides that include a C-terminal extension, as well as antibodies and antibody conjugates containing such modified light chain polypeptides, where the C-terminal extension includes one or more cysteine residues. Conjugates that include an antibody of the present disclosure conjugated to an agent via the cysteine residue of the C-terminal amino acid extension are also provided. The present disclosure further provides nucleic acids encoding an antibody light chain polypeptide that includes a C-terminal amino acid extension including a cysteine residue. Pharmaceutical compositions including the antibodies or conjugates of the present disclosure are also provided, as are methods of making and use of the modified anti-bodies and conjugates of the present disclosure.Type: GrantFiled: December 23, 2014Date of Patent: December 28, 2021Inventors: John Babcook, James R. Rich, Jan Peter Bergqvist, Stuart Daniel Barnscher
-
Patent number: 10675355Abstract: VAR2CSA-drug conjugates having biological activity are disclosed. Methods associated with preparation and use of such conjugates, as well as pharmaceutical compositions comprising such conjugates, are also disclosed.Type: GrantFiled: December 29, 2014Date of Patent: June 9, 2020Assignees: VAR2 PHARMACEUTICALS APS, ZYMEWORKS INC.Inventors: James R. Rich, John Babcook, Ali El-Salanti, Mads Daugaard, Madeleine Dahlback, Bradley J. Hedberg, Geoffrey C. Winters, Alexander L. Mandel, Elyse Marie Josée Bourque, Tom Han Hsiao Hsieh
-
Patent number: 10517958Abstract: VAR2CSA-drug conjugates for targeting and inhibiting the growth of cancer cells that have developed resistance to a platinum drug and the use of the conjugates in the treatment of platinum drug-resistant cancers. VAR2CSA-drug conjugates (VDCs) comprise a VAR2CSA polypeptide that is capable of binding to oncofetal chondroitin sulfate (ofCS) and one or more toxins having anti-cancer activity conjugated to the VAR2CSA polypeptide, either directly or via a linker.Type: GrantFiled: October 4, 2017Date of Patent: December 31, 2019Assignees: ZYMEWORKS INC., VAR2 PHARMACEUTICALS APSInventors: John Babcook, James R. Rich, Mads Daugaard, Ali El-Salanti
-
Publication number: 20190269785Abstract: Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.Type: ApplicationFiled: February 11, 2019Publication date: September 5, 2019Inventors: Geoffrey C. WINTERS, Alexander Laurence MANDEL, James R. RICH, Bradley John HEDBERG, Tom Han Hsiao HSIEH, Elyse Marie Josée BOURQUE, John BABCOOK
-
Patent number: 10201614Abstract: Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.Type: GrantFiled: March 14, 2014Date of Patent: February 12, 2019Assignee: ZYMEWORKS INC.Inventors: Geoffrey C. Winters, Alexander Laurence Mandel, James R. Rich, Bradley John Hedberg, Tom Han Hsiao Hsieh, Elyse Marie Josée Bourque, John Babcook
-
Publication number: 20180193473Abstract: VAR2CSA-drug conjugates for targeting and inhibiting the growth of cancer cells that have developed resistance to a platinum drug and the use of the conjugates in the treatment of platinum drug-resistant cancers. VAR2CSA-drug conjugates (VDCs) comprise a VAR2CSA polypeptide that is capable of binding to oncofetal chondroitin sulfate (ofCS) and one or more toxins having anti-cancer activity conjugated to the VAR2CSA polypeptide, either directly or via a linker.Type: ApplicationFiled: October 4, 2017Publication date: July 12, 2018Inventors: John BABCOOK, James R. RICH, Mads DAUGAARD, Ali EL-SALANTI
-
Publication number: 20180117163Abstract: VAR2CSA-drug conjugates having biological activity are disclosed. Methods associated with preparation and use of such conjugates, as well as pharmaceutical compositions comprising such conjugates, are also disclosed.Type: ApplicationFiled: December 29, 2014Publication date: May 3, 2018Applicants: ZYMEWORKS INC., VAR2 PHARMACEUTICALS APSInventors: James R. RICH, John BABCOOK, Ali EL-SALANTI, Mads DAUGAARD, Madeleine DAHLBACK, Bradley J. HEDBERG, Geoffrey C. WINTERS, Alexander L. MANDEL, Elyse Marie Josée BOURQUE, Tom Han Hsiao HSIEH
-
Publication number: 20170246310Abstract: VAR2CSA-drug conjugates having biological activity are disclosed. Methods associated with preparation and use of such conjugates, as well as pharmaceutical compositions comprising such conjugates, are also disclosed.Type: ApplicationFiled: December 29, 2014Publication date: August 31, 2017Applicants: ZYMEWORKS INC., VAR2 PHARMACEUTICALS APSInventors: James R. RICH, John BABCOOK, Ali EL-SALANTI, Mads DAUGAARD, Madeleine DAHLBACK, Bradley J. HEDBERG, Geoffrey C. WINTERS, Alexander L. MANDEL, Elyse Marie Josée BOURQUE, Tom Han Hsiao HSIEH
-
Publication number: 20170008970Abstract: The present disclosure provides light chain polypeptides that include a C-terminal extension, as well as antibodies and antibody conjugates containing such modified light chain polypeptides, where the C-terminal extension includes one or more cysteine residues. Conjugates that include an antibody of the present disclosure conjugated to an agent via the cysteine residue of the C-terminal amino acid extension are also provided. The present disclosure further provides nucleic acids encoding an antibody light chain polypeptide that includes a C-terminal amino acid extension including a cysteine residue. Pharmaceutical compositions including the antibodies or conjugates of the present disclosure are also provided, as are methods of making and use of the modified anti-bodies and conjugates of the present disclosure.Type: ApplicationFiled: December 23, 2014Publication date: January 12, 2017Inventors: John BABCOOK, James R. RICH, Jan Peter BERGQVIST, Stuart Daniel BARNSCHER
-
Patent number: 9522876Abstract: Compounds having cytotoxic and/or anti-mitotic activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4 and R5 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having structure (I).Type: GrantFiled: March 14, 2014Date of Patent: December 20, 2016Assignee: ZYMEWORKS INC.Inventors: Geoffrey C. Winters, Alexander L. Mandel, Bradley J. Hedberg, John Babcook, James R. Rich, Tom Han Hsiao Hsieh, Elyse Marie Josée Bourque
-
Publication number: 20160038606Abstract: Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.Type: ApplicationFiled: March 14, 2014Publication date: February 11, 2016Inventors: Geoffrey C. WINTERS, Alexander Laurence MANDEL, James R. RICH, Bradley John HEDBERG, Tom Han Hsiao HSIEH, Elyse Marie Josée BOURQUE, John BABCOOK
-
Patent number: 8785600Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: GrantFiled: October 22, 2010Date of Patent: July 22, 2014Assignees: Millennium Pharmaceuticals, Inc., Amgen British ColumbiaInventors: Samuel S. Nam, Edward A. Greenfield, Theresa L. O'Keefe, Shixin Qin, John Babcook
-
Patent number: 8779108Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.Type: GrantFiled: November 24, 2010Date of Patent: July 15, 2014Assignee: MedImmune, LimitedInventors: Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcook, Ian Nevin Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Stewart, Kathleen Ann Mulgrew
-
Publication number: 20140105905Abstract: The present embodiments are related to high-affinity antibodies directed to IL-8, methods of making and characterizing such antibodies and uses of such antibodies. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided.Type: ApplicationFiled: November 20, 2013Publication date: April 17, 2014Applicant: Amgen Fremont, Inc.Inventors: John Babcook, Palaniswami Rathanaswami, Orit Foord, Jaspal S. Kang
-
Patent number: 8604174Abstract: The present embodiments are related to high-affinity antibodies directed to IL-8, methods of making and characterizing such antibodies and uses of such antibodies. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided.Type: GrantFiled: April 18, 2006Date of Patent: December 10, 2013Assignee: Amgen Inc.Inventors: John Babcook, Palaniswami Rathanaswami, Orit Foord, Jaspal S. Kang
-
Patent number: 8431130Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.Type: GrantFiled: July 26, 2010Date of Patent: April 30, 2013Assignee: Abbott LaboratoriesInventors: Tariq Ghayur, Boris Labkovsky, Jeffrey W. Voss, Larry Green, John Babcook, Xiao-chi Jia, James Wieler, Jaspal Singh Kang, Brad Hedberg
-
Publication number: 20130034559Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed.Type: ApplicationFiled: November 24, 2010Publication date: February 7, 2013Applicant: Medlmmune LimitedInventors: Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcook, Ian Nevin Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Stewart, Kathleen Ann Mulgrew